TY - JOUR
T1 - Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir
T2 - A case series
AU - D'Ettorre, Gabriella
AU - Barbarini, G.
AU - Corti, F.
AU - Gobber, M.
AU - Pastecchia, C.
AU - Ricci, G. L.
AU - Siciliano, M.
AU - Annicchiarico, B. E.
AU - Vullo, V.
PY - 2010/6
Y1 - 2010/6
N2 - We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6±14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4±4.5 months. Seroconversion occurred in all patients, after a mean time of 8.0±3.7 months. In HBeAg negative patients, mean time to HBsAg clearance and to seroconversion were 9.2±5.9 and 6.8±4.0 months, respectively. In HBeAg positive patients, mean time to HBsAg clearance and to seroconversion were 9.7±0.6 months and 10.0±2.6 months, respectively. In this case series, seroconversion was maintained and was observed both in HBeAg positive patients and in HBeAg negative patients. Therefore, it may be preliminarily suggested that treatment with entecavir could be associated to HBsAg seroconversion in a short period of time, in both HBeAg positive and HBeAg negative HBV patients.
AB - We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6±14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4±4.5 months. Seroconversion occurred in all patients, after a mean time of 8.0±3.7 months. In HBeAg negative patients, mean time to HBsAg clearance and to seroconversion were 9.2±5.9 and 6.8±4.0 months, respectively. In HBeAg positive patients, mean time to HBsAg clearance and to seroconversion were 9.7±0.6 months and 10.0±2.6 months, respectively. In this case series, seroconversion was maintained and was observed both in HBeAg positive patients and in HBeAg negative patients. Therefore, it may be preliminarily suggested that treatment with entecavir could be associated to HBsAg seroconversion in a short period of time, in both HBeAg positive and HBeAg negative HBV patients.
KW - Entecavir
KW - HBV infection
KW - Seroconversion
UR - http://www.scopus.com/inward/record.url?scp=77955801583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955801583&partnerID=8YFLogxK
M3 - Article
C2 - 20712263
AN - SCOPUS:77955801583
VL - 14
SP - 551
EP - 554
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
SN - 1128-3602
IS - 6
ER -